Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast

Rhea-AI Summary

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has announced the release date for its third quarter 2021 financial results, set for November 4, 2021. Following the release, a conference call is scheduled at 9:15 a.m. ET, open to the public through telephone and webcast. Key details include dial-in numbers and a conference ID for participants. Sangamo is a clinical-stage biopharmaceutical firm focused on genomic medicines, leveraging proprietary technology to develop solutions for patients with unmet medical needs. For more information, visit sangamo.com.

Positive

• Scheduled release of Q3 2021 financial results, indicating transparency.
• Public conference call offering business and clinical updates.

Negative

• None.

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021. The press release will be followed by a conference call at 9:15 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business and clinical updates.

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 5178059. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 5178059.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005261/en/

Investor & Media Inquiries

Aron Feingold

628-252-7494

afeingold@sangamo.com

Source: Sangamo Therapeutics, Inc.

FAQ

When will Sangamo Therapeutics release its Q3 2021 financial results?

Sangamo Therapeutics will release its Q3 2021 financial results on November 4, 2021.

What time is the conference call for Sangamo's Q3 2021 financial results?

The conference call is scheduled for 9:15 a.m. ET on November 4, 2021.

How can I access the conference call for Sangamo's Q3 results?

You can access the conference call via telephone at (877) 377-7553 for domestic callers and (678) 894-3968 for international callers.

What is the conference ID for Sangamo's conference call?

The conference ID number for the call is 5178059.

Where can I find more information about Sangamo Therapeutics?

More information about Sangamo Therapeutics can be found on their website at www.sangamo.com.